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Direct maxacalcitol (OCT) injection into a parathyroid gland
(PTG) ameliorates several important etiologic factors of
resistance to medical treatments for secondary
hyperparathyroidism (s-HPT): the upregulations of vitamin D
receptor (VDR) and Ca-sensing receptor (CaSR) in PTGs and
the regression of PTG hyperplasia by the induction of
apoptosis. In this study, we evaluated the bone
histomorphology on the basis of maintaining these effects in
advanced s-HPT. Five/six nephrectomized Sprague–Dawley
rats were fed a high-phosphorus and low-calcium diet for 8
weeks. These rats were divided into four treatment groups:
(1) basic uremic (at the baseline), (2) direct OCT single
injection into PTGs (DI-OCT) followed by OCT intravenous
administration for 4 weeks (IV-OCT), (3) direct vehicle
injection and IV-OCT, and (4) no treatment for an additional
4 weeks. The effects of these treatments on serum
intact-parathyroid hormone (PTH) level, PTG weight, VDR and
CaSR expression levels in PTGs, and bone histomorphometric
parameters were investigated. In the DI-OCTþ IV-OCT group,
the significant decrease in serum intact-PTH level was
maintained by the following IV-OCT. A significant decrease in
PTG weight and the upregulations of VDR and CaSR
expression levels in PTGs were also observed. Bone
histomorphometric analysis showed significant
improvements in osteitis fibrosa in both cancellous and
cortical bones. However, these findings were not observed in
the other groups. These results suggest that osteitis fibrosa
caused by advanced s-HPT can be successfully reversed by a
control of PTH at an appropriate level through the
improvement of PTG hyperplasia as induced by
DI-OCTþ IV-OCT.
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Renal osteodystrophy is a general term for skeletal abnor-
malities in patients with end-stage renal disease. This
condition consists of variegated bone histopathological
features. Parathyroid hormone (PTH) plays a central role,
particularly in bone turnover rate, in this disorder. High and
low bone turnover rates have been attributed to high and low
levels of PTH, respectively, and both conditions may induce
not only skeletal abnormalities but also cardiovascular
disorders because of ectopic calcification in vascular tissues
caused by abnormalities of mineral metabolism. Thus, the
maintenance of appropriate levels of PTH, calcium (Ca), and
phosphorus (P) is required for the improvement of the
prognosis of these patients.1–4
Hyperplasia of the parathyroid glands (PTGs) in patients
with end-stage renal disease causes secondary hyperpara-
thyroidism (s-HPT), the main feature of which is a high level
of PTH. The early stage of s-HPT can be controlled by
medical treatments with P binders and vitamin D supple-
mentation among others. However, advanced s-HPT, char-
acterized by severely hyperplastic PTGs called nodular
hyperplasia, is unresponsive to these medical treatments
because of the hypersynthesis and hypersecretion of PTH and
the low expression levels of vitamin D receptor (VDR) and
Ca-sensing receptor (CaSR) in parathyroid cells (PTCs),
which are concomitant with the progression of hyperplasia.5,6
Moreover, the relationship between the proliferation activity
of PTCs and the decreases in both expression levels of VDR
and CaSR in PTCs is also confirmed in this condition.7,8
Thus, it is considered that the most important target for the
management of s-HPT is the control of PTG hyperplasia.
Ultrasound-guided direct injection of calcitriol or its
analog into hyperplastic PTGs induced a significant decrease
in PTH level without changes in Ca and P levels in patients
with advanced s-HPT, which was resistant to other medical
treatments including the conventional administration of
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2006 International Society of Nephrology
Received 2 December 2005; revised 19 February 2006; accepted 14
March 2006; published online 21 June 2006
Correspondence: K Shiizaki, Division of Nephrology and Blood Purification
Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama
641-0012, Japan. E-mail: shiizaki@wakayama-med.ac.jp
486 Kidney International (2006) 70, 486–495
these agents. Moreover, it was reported that the decreased
PTH levels was maintained by conventional medical treat-
ments subsequent to the direct injection and that one of the
mechanisms underlying these favorable clinical effects was
the regression of PTG hyperplasia caused by the induction of
apoptosis of PTCs.9,10 The development of animal models of
advanced s-HPT and a method of direct injection into PTGs
have made it possible to investigate the details of these effects
in PTCs. This novel treatment for advanced s-HPT can
simultaneously ameliorate the important etiological factors
of resistance to medical treatments for s-HPT: the marked
suppression of PTH synthesis and secretion, the upregu-
lations of VDR and CaSR, and the induction of apoptosis of
PTCs.11 However, only the short-term effects of these
ameliorations were confirmed and the effects of this
treatment on bones as the most important target organ of
PTH were not investigated.
In the present study, we examined the maintenance
of the above-mentioned cellular effects by intravenous
maxacalcitol (OCT) administrations following a direct OCT
injection into hyperplastic PTGs, as well as the histomorpho-
metric alterations in cancellous and cortical bones induced in
the control of s-HPT on the basis of ameliorating these cellular
characteristics.
RESULTS
Changes in laboratory data
Significant differences in all data among the treatment groups
at the baseline were not observed. Direct OCT injection
(DI-OCT) significantly decreased serum intact-PTH level
with respect to the original level and this decreased level
was maintained for 4 weeks by the following intravenous
OCT administrations (IV-OCT). However, direct vehicle
injection (DI-vehicle) and the following IV-OCT did
not decrease this level. Thus, it is considered that the effect
of vehicle and mechanical stress associated with the
direct injection failed to decrease serum intact-PTH level
and that the s-HPT of rats worsened as it was unresponsive
to IV-OCT. There were no marked changes in serum Ca2þ
or P level following these treatments; moreover, a significant
difference in serum Ca2þ or P level between the DI-
OCTþ IV-OCT and DI-vehicleþ IV-OCT groups was not
observed. The abnormalities of these biochemical data in
the uremic control group gradually worsened with time
(Table 1). However, a significant difference in survival rate
among all treatment groups was not observed in this
experimental period.
Changes in PTG weight
The PTG per total body weight ratio of the DI-OCTþ IV-
OCT group significantly decreased compared with that of the
basic uremic group; however, that of the DI-vehicleþ IV-
OCT group increased similarly to that of the uremic control
group. Thus, it is considered that DI-OCT induced PTG
regression and IV-OCT maintained this. IV-OCT alone
cannot attenuate PTG hyperplasia in this advanced s-HPT
model (Figure 1).
Changes in PTH, VDR, and CaSR mRNA expression levels
determined by real-time polymerase chain reaction (PCR)
The PTH/glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA ratios of the DI-OCTþ IV-OCT and
DI-vehicleþ IV-OCT groups were significantly lower than
those of the basic uremic and uremic control groups. Both the
VDR/GAPDH and CaSR/GAPDH mRNA ratios of the DI-
OCTþ IV-OCT group were significantly higher than those of
Table 1 | Baseline data and time course changes in serum intact-PTH, ionized Ca, and P levels
Parameter (unit)
Normal
(N=10)
Basic uremic
(N=8)
DI-OCT+IV-OCT
(N=8)
DI-vehicle +IV-OCT
(N=8)
Uremic control
(N=8)
P-value of
ANOVA
Body weight (g) (52377) 435732 413748 441744 415750 0.4807
Hb (g/dl) (16.870.8) 13.171.4 13.471.2 13.671.2 12.571.2 0.3191
Hct (%) (49.472.0) 37.973.7 39.073.2 39.973.5 36.973.5 0.3554
BUN (mg/dl) (15.571.7) 58.0712.0 60.8715.4 56.1712.8 55.874.5 0.8275
Cr (mg/dl) (0.3870.04) 0.9670.27 0.9970.17 1.0370.28 1.0170.17 0.9484
Alb (g/dl) (3.4570.12) 3.8070.15 3.7370.10 3.8470.14 3.6570.28 0.1985
Ca2+ (mmol/l)
Baseline — 0.9370.15 0.9570.11 0.9370.16 1.0070.05 0.5698
2 weeks — — 0.9670.16 0.9770.12 0.9470.08* 0.8878
4 weeks (1.3770.02) — 1.1270.11**,##(b) 1.0070.13* 0.9070.06** 0.0020
P (mg/dl)
Baseline — 17.376.6 15.175.9 15.575.2 14.373.5 0.7443
2 weeks — — 17.477.0 14.573.8 18.473.3** 0.2757
4 weeks (5.970.3) — 17.374.8 17.774.8 20.871.8** 0.2048
Intact-PTH (pg/ml)
Baseline — 299471500 26077806 306371326 307071497 0.8784
2 weeks — — 9367439**,##(a,b) 375171662 474471580** o0.0001
4 weeks (38715) — 6197243**,##(a,b) 422872218**,#(b) 668071486** o0.0001
Alb, albumin; ANOVA, analysis of variance; BUN, blood urea nitrogen; Ca, calcium; Cr, creatinine; Hb, hemoglobin; Hct, hematocrit; P, phosphorus; PTH, parathyroid hormone.
Data are means7s.d. Baseline and corresponding time data among all the treatment groups in uremic rats were analyzed by analysis of variance (ANOVA).*Po0.05 and
**Po0.01 indicate significant differences at 2 or 4 weeks compared with those at the baseline in each group, and ##Po0.01 indicate significant differences among treatment
groups at the corresponding time point (a: vs DI-vehicle+IV-OCT, b: vs uremic control groups).
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any other treatment groups. However, the improvements of
these expression levels were not sufficient to reach the same
levels as those of the normal group. IV-OCT alone signifi-
cantly decreased the PTH mRNA level without increasing
VDR or CaSR mRNA levels in this advanced s-HPT model
(Table 2).
Immunohistochemical analysis of VDR, CaSR, and
proliferating cell nuclear antigen (PCNA) expressions
Immunohistochemical analysis revealed that both VDR and
CaSR expression levels following DI-OCTþ IV-OCT were
markedly high and that the differences between the DI-
OCTþ IV-OCT group and other treatment groups were
significant (more than 10 and 30-fold higher in VDR- and
CaSR-labeling indexes, respectively). The PCNA expression
level following DI-OCTþ IV-OCT was lower and the
difference in PCNA-labeling index was also significant (about
10-fold lower) (Figure 2). However, the improvements of
these expression levels were not sufficient to reach the same
levels as those of the normal group.
Histopathological and histomorphometrical analyses of
cancellous bone
In the photographs of the basic uremic, DI-vehicleþ IV-
OCT, and uremic control groups, enhanced bone and osteoid
formations, hypomineralization of bone, bone erosion with
active osteoclasts, double labeling, and diffuse and irregular
labeling are observed. These findings indicate pathologic
bone features associated with advanced s-HPT. However, in
the bone treated by DI-OCTþ IV-OCT, an enhanced bone
lamellar structure formation, attenuations of osteoid forma-
tion and bone erosion, and regular labeling were noted, and
these findings were almost the same as those of the normal
group (Figure 3).
Bone histomorphometrical analysis revealed that all
parameters in Figure 4 of the DI-OCTþ IV-OCT group
were significantly improved compared with those of the
basic uremic group. Moreover, the values of all parameters
except BFR/BS decreased to almost the same values as those
of the normal group. Those of DI-vehicleþ IV-OCT group
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Figure 1 | Ratio of PTG with respect to total body weight.
(The number of rats in each of the basic uremic, DI-OCTþ IV-OCT,
DI-vehicleþ IV-OCT, and uremic control groups was eight).
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VDR CaSR PCNA
Figure 2 | Immunohistochemical staining for VDR, CaSR, and
PCNA in PTCs. Representative micrographs of immunohistochemical
staining for VDR, CaSR, and PCNA in PTCs for the individual treatment
groups are shown. Original magnification  400.
Table 2 | PTH/GAPDH, VDR/GAPDH, and CaSR/GAPDH mRNA ratios of parathyroid gland
Gene expression Normal (N=6) Basic uremic (N=8) DI-OCT+IV-OCT (N=8) DI-vehicle+IV-OCT (N=8) Uremic control (N=8)
PTH/GAPDH (0.70970.290) 1.27470.194 0.71870.220**,##(b) 0.80370.052**,##(b) 1.14070.080
VDR/GAPDH (1.84670.372) 0.56370.372 1.58570.771**,##(a, b) 0.74470.356 0.68470.384
CaSR/GAPDH (1.73970.740) 0.64470.164 1.15770.151**,##(a, b) 0.66970.099 0.76270.372
CaSR, calcium-sensing receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PTH, parathyroid hormone.
Data are means7s.d. **Po0.01 indicate significant differences compared with those of basic uremic group, and ##Po0.01 indicate significant differences among treatment
groups at the completion of study (a: vs DI-vehicle+IV-OCT, b: vs uremic control groups).
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also showed the same values as those of the uremic control
group.
Histopathological and histomorphometrical analyses of
cortical bone
In the photograph of the basic uremic group, the changes
consistent with s-HPT were not remarkable. However, the
DI-vehicleþ IV-OCT and uremic control groups showed the
pathological features of advanced s-HPT with an increased
thickness of cortical bone and a markedly increased
intracortical porosity area. DI-OCTþ IV-OCT induced a
pronounced suppression of this progression (Figure 5).
Bone histomorphometrical analysis showed that DI-
OCTþ IV-OCT significantly suppressed the decrease in
Ma.Ar and the increases in Ct.Ar/T.Ar, Po.Ar/Ct.Ar, and
Hy.Md.Ar/Ct.Ar; however, DI-vehicleþ IV-OCT failed to do
this (Figure 6).
Histopathological and histomorphometrical analyses
of endosteal surface, intracortical area, and periosteal
surface in cortical bone
In the photographs of the DI-vehicleþ IV-OCT and uremic
control groups, an enhanced osteoid formation, hypominer-
alization of bone, bone erosion with active osteoclasts, an
increased porosity area with fibrous tissue, double labeling,
and diffuse and irregular labeling were observed. These
findings indicate the pathologic bone features associated with
advanced s-HPT. However, these features were mild in the
bone of the basic uremic and DI-OCTþ IV-OCT groups
(Figure 7).
Bone histomorphometrical analysis of the endosteal
surface, intracortical area, and periosteal surface showed that
OS/BS, MS/BS, MAR, and BFR/BS were markedly high even
in the basic uremic group and that DI-vehicleþ IV-OCT
failed to decrease these abnormally high values. However, DI-
OCTþ IV-OCT significantly decreased them to the same
values as those of the normal group and markedly suppressed
the increase in Fb.Ar/Ct.Ar in the intracortical area (Table 3).
DISCUSSION
Advanced secondary hyperparathyroidism (advanced s-HPT),
which is characterized by severely hyperplastic PTGs and a
very high level of serum PTH, indicates a poor prognosis in
patients with end-stage renal disease owing to the complica-
tions of cardiovascular disorders.1–4 Both high and low bone
turnover rates caused by high and low levels of PTH,
respectively, result in an abnormal mineral metabolism. Thus,
it is well accepted that the target of s-HPT treatment is the
prevention of cardiovascular disorders by promoting the
normalization of both bone turnover rate and mineral
metabolism. Our previous studies showed that the direct
injection of calcitriol or OCT into hyperplastic PTGs with the
subsequent conventional administration of these agents
induces a significant decrease in serum PTH level and
maintains this at an appropriate level without changes in
serum Ca and P levels, and also showed that some
mechanisms underlying this effect involve the simultaneous
improvements in the various etiological factors for the
resistance to medical treatments in advanced s-HPT.9–11 The
present study showed that the control of PTH levels by
promoting the normalization of these factors by this
treatment (DI-OCT) improved the histopathological features
of both cancellous and cortical bones in the advanced s-HPT
animal model.
Biochemical findings indicate that DI-OCTþ IV-OCT
significantly decreased serum intact-PTH level; however, DI-
vehicleþ IV-OCT only arrested a further increase in this level
(Table 1). The cellular differences between these treatments
were the marked regression of hyperplasia and the upregula-
tions of VDR and CaSR expression levels in PTCs (Figures 1
and 2). Previous reports showed that OCT mediated the
suppression of PTH mRNA expression in normal and uremic
animals;12–14 however, our present data showed that DI-
vehicleþ IV-OCT could not decrease serum intact-PTH level,
Basic
uremic
Uremic
control
DI-OCT
+IV-OCT 
DI-vehicle
+IV-OCT 
Normal
Figure 3 | Effects of uremia-induced hyperparathyroidism and
DI-OCTþ IV-OCT on cancellous bone. In the bone of the basic
uremic group, various features associated with hyperparathyroidism
were observed. However, DI-OCTþ IV-OCT ameliorated these
features. Original magnification  160.
Kidney International (2006) 70, 486–495 489
K Shiizaki et al.: DI-OCT improves skeletal changes in s-HPT o r i g i n a l a r t i c l e
despite inducing PTH mRNA expression at the same level as
that induced by DI-OCTþ IV-OCT. Thus, it was considered
that the suppression of PTH mRNA expression alone by IV-
OCT at a high dose (2.5 mg/kg body weight: 150 mg for a 60 kg
human; three times/week) did not sufficiently decrease serum
PTH level and that the improvements in the above-
mentioned etiologic factors, in particular PTG hyperplasia,
were very important for PTH control in advanced s-HPT.
DI-OCT induced cell apoptosis and upregulated both
VDR and CaSR expression levels in PTCs.11 Previous reports
showed that PCNA expression level is associated with VDR or
CaSR expression levels in PTCs.7,8 Moreover, it was reported
that calcitriol or its analogs mediate the suppressions of the
PTC proliferation and PTG growth.15–17 We confirmed the
presence of few TUNEL-positive PTCs in the DI-OCTþ IV-
OCT group but there was no significant difference in the
number of these cells among all the treatment groups (data
not shown). Thus, we considered that the decreased cell
number associated with the induction of apoptosis in the
early phase after DI-OCT and the suppression of PTC
proliferation by IV-OCT subsequent to VDR and CaSR
upregulations were the major mechanisms underlying the
regression of hyperplastic PTGs in this treatment.
Previous reports showed that the conventional adminis-
tration of OCT or another vitamin D analog mediates the
effective prevention of bone disease and ameliorates the
established bone histopathology and bone histomorpho-
metric abnormalities in uremic animals and patients.18–20
However, the subjects of these previous studies had mild
s-HPT, whose serum PTH levels were significantly decreased
by the conventional administration of these agents. In
general, patients with advanced s-HPT, which is unresponsive
to conventional medical treatments, undergo the surgical
removal of PTGs. Parathyroidectomy is very effective in
decreasing serum PTH and Ca levels; however, it was
reported that this treatment often induces a low bone
turnover rate.21,22 A low turnover and adynamic bone
diseases caused by an excessive decrease in PTH level,
particularly after parathyroidectomy, could affect the devel-
opment and progression of arterial calcification.2 Moreover,
parathyroidectomy can be complicated by some problems,
such as the necessity for general anesthesia, the hyper- or
hypofunction of autotransplanted PTGs, and psychological
distress. Thus, therapeutic tools for the appropriate control
of both PTH level and bone turnover rate are required for
these patients.
In cancellous bone, significant abnormalities were present
at the baseline (basic uremic group). The additional 4 weeks
with the high-P and low-Ca diet worsened these abnormal-
ities. DI-OCTþ IV-OCT normalized the bone structures,
which had been worsened by uremia and this diet; the
structures were almost the same as those of the normal group
(Figure 3). However, DI-vehicleþ IV-OCT failed to do this;
instead, it worsened bone abnormalities despite using the
same dose of IV-OCT as that in DI-OCTþ IV-OCT. The
most important difference between these treatments was the
PTH control following the improvement in the above-
mentioned etiologic factors of advanced s-HPT induced by
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Figure 4 | Bone histomorphometric determinations of cancellous bone. The dotted areas represent the means7s.d. for the normal
group. (The number of normal rats and uremic rats in the basic uremic, DI-OCTþ IV-OCT, DI-vehicleþ IV-OCT, and uremic control groups were
10, 8, 8, 8, and 8, respectively).
490 Kidney International (2006) 70, 486–495
o r i g i n a l a r t i c l e K Shiizaki et al.: DI-OCT improves skeletal changes in s-HPT
the single DI-OCT. Bone histomorphometric analysis also
confirmed significant improvements in many parameters
(Figure 4).
In cortical bone, the histopathological features of osteitis
fibrosa were not so remarkable at the baseline. These features
were pronounced in the DI-vehicleþ IV-OCT and uremic
control groups (e.g., increased thickness of cortical bone and
markedly increased intracortical porosity area). High PTH
level induced by uremia and high-P diet progressively
worsened these abnormalities. However, DI-OCTþ IV-OCT
successfully suppressed this progression (Figure 5). Bone
histomorphometric analysis showed excessive bone forma-
tion (very high values of OS/BS, MS/BS, MAR, and BFR/BS)
in the endosteal surface, the intracortical area, and the
periosteal surface at the baseline (Table 3). The normalization
of bone turnover rate by the sustained decrease in PTH level
effectively prevented the formation of sponge-like cortical
bone with many porosity areas. PTH binding to the PTH/
PTH-related protein receptor on the surface of osteoblasts
activates not only the osteoblast itself but also osteoclasts by
the expression of the receptor activator of the NF-kB
ligand.23,24 Therefore, it is considered that an excessively
high PTH level induces a high bone turnover rate (osteitis
fibrosa). This novel treatment made it possible to markedly
decrease PTH level by improving PTC characteristics and
PTG hyperplasia and to successfully treat osteitis fibrosa in
advanced s-HPT. However, the detailed mechanism under-
lying these effects remains unclarified; therefore, more precise
studies are required.
In conclusion, DI-OCTþ IV-OCT effectively decreased
serum PTH level and normalized the above-mentioned
etiologic factors of advanced s-HPT and these effects
successfully ameliorated osteitis fibrosa (high bone turnover
rate). Thus, it is considered that this novel treatment could
improve the prognosis of dialysis patients with advanced
s-HPT.
MATERIALS AND METHODS
Animals
On 7-week-old male Sprague–Dawley rats, five/six nephrectomies
were performed under intraperitoneal pentobarbital anesthesia
(50 mg/kg body weight). The rats were fed a normal diet (0.9% P,
1.12% Ca) until 1 week after this procedure and were then switched
to a high-P and low-Ca diet (1.2% P, 0.4% Ca) for 8 weeks. This
procedure has been described in detail.11 The feed was obtained
from Oriental Yeast, Inc. (Chiba, Japan). The Animal Studies
Committee of Wakayama Medical University approved all animal
experimental protocols.
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Figure 6 | Bone histomorphometric determinations of cortical
bone. The dotted areas represent the means7s.d. for the normal
group. (The number of normal rats and uremic rats in the basic
uremic, DI-OCTþ IV-OCT, DI-vehicleþ IV-OCT, and uremic control
groups were 10, 8, 8, 8, and 8, respectively).
Basic uremic Uremic control
DI-OCT+IV-OCT 
DI-vehicle+IV-OCT 
Normal
Figure 5 | Effects of uremia-induced hyperparathyroidism
and DI-OCTþ IV-OCT on cortical bone. In the bone of the basic
uremic group, the changes associated with uremia-induced
hyperparathyroidism were not remarkable. DI-OCTþ IV-OCT
suppressed the progression of cortical bone deformities. Original
magnification  32.
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Experimental protocols
The bilateral PTGs of the rats were exposed surgically and were
directly injected with 10ml of maxacalcitol (22-oxacalcitriol: OCT;
10 mg/ml) (DI-OCT) or its vehicle (phosphate buffer containing
0.01% polyoxyethylene sorbitan monolaurate and 0.2% ethanol; pH
8.0, isotonic solution; DI-vehicle) using a 30-gauge needle
(exclusively made by Tochigi Seikou Co., Inc., Tochigi, Japan).
Immediately after the injection, the solution that had leaked from
the PTGs was washed away with saline and removed. These
procedures were performed under diethylether inhalation. Pre-
viously, we reported that the actual injected volume of the solution
was similar to the original PTG volume of the rats (2.4770.65 ml/
One PTG; N¼ 10). This procedure has been described in detail.11
At 2 days after this treatment (a single treatment with DI-OCT or
DI-vehicle), the rats started receiving intravenous OCT administra-
tions (2.5mg/kg body weight; three times/week) for 4 weeks (IV-
OCT). In this study, we examined the following experimental groups:
(1) basic uremic group (N¼ 8): the rats at the baseline (completion
of 8 weeks of the high-P and low-Ca diet); (2) DI-OCTþ IV-OCT
group (N¼ 8); (3) DI-vehicleþ IV-OCT group (N¼ 8); and (4)
uremic control group (N¼ 8) (additional 4 weeks without any
treatment). The diet was not changed in any experimental groups
until the completion of the study. Figure 8 shows the schematic
experimental protocols. For all reference data, an age-matched
normal control ((5) normal group; N¼ 10) was added.
Laboratory measurements
Serum intact-PTH, Ca2þ , and P levels, and other data were deter-
mined before (baseline data) and at 2 and 4 weeks after DI-OCT or
DI-vehicle. Serum intact-PTH level was measured by a two-antibody
method using a rat intact-PTH enzyme-linked immunosorbent
assay kit (Immutopics, Inc., CA, USA). This kit can measure
between 1.6 and about 2000 pg/ml; therefore, the samples of normal
and all uremic groups were diluted with the attached 0 pg/ml
Standard at 1:1 and 1:10, respectively, and analyzed together. All
standards, controls, and test samples were assayed in duplicate and
averages were taken. Hemoglobin, hematocrit, and Ca2þ levels were
measured using an i-STAT Portable Clinical Analyzer (i-STAT
Corporation, NJ, USA). Other data were determined using an
automated analyzer (DRI-CHEM3500V, Fuji Film, Tokyo, Japan).
For the normal group, the same data were collected at the
completion of this study.
Isolation of total RNA and real-time PCR for PTH, VDR, and
CaSR
At the completion of this study, both PTGs were removed and
weighed using LA230S (Sartorius AG, Goettingen, Germany). One
PTG (right side) was processed as follows. Total RNA was prepared
from the PTG specimen using TRIzol reagent (Life Technologies,
MD, USA). Total RNA (2 mg) was reverse-transcribed using oligo
(dT) as a primer (Life Technologies, MD, USA) for PCR, as
described in a previous report.9
The TaqMans probe and primers for PTH, VDR, CaSR, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were pur-
chased from TaqMans Gene Expression Assays (Perkin–Elmer
Applied Biosystems, Foster City, CA, USA). The assay IDs of sets of
the PTH, VDR, CaSR, and GAPDH primers and TaqMans probes
were Rn00566882_m1, Rn00566976_m1, Rn00566496_m1, and
Rn99999916_s1, respectively. TaqMans PCR reactions were per-
formed in 50-ml volumes. The TaqMans PCR reaction mixture was
25 ml of 2 TaqMans Universal PCR Master Mix (4304437,
Applied Biosystems), 2.5 ml of primer and TaqMans probe set, and
2 ml of cDNA. Amplification and detection were performed using an
ABI 7500 system (Perkin–Elmer Applied Biosystems). The thermal
profile for PCR was 501C for 2 min, 951C for 10 s, and 601C for
1 min. Each sample was measured in duplicate, and the expression
level of the tested gene was normalized to a GAPDH standard curve
run in duplicate on the same plate, and then the PTH/GAPDH,
VDR/GAPDH, and CaSR/GAPDH mRNA ratios for individual
samples were averaged.
Immunohistochemistry for VDR, CaSR, and PCNA
The other PTG (left side) was fixed with 4% paraformaldehyde
phosphate-buffered saline for 8 h and paraffin embedded. Immuno-
Basic 
uremic
DI-OCT 
+IV-OCT
DI-vehicle 
+IV-OCT
Uremic
control
Normal
Figure 7 | Effects of uremia-induced hyperparathyroidism and
DI-OCTþ IV-OCT on intracortical area of cortical bone. The
cortical bones of DI-vehicleþ IV-OCT and uremic control groups
appeared similar to a cancellous bone (sponge-like cortical bone)
with pathologic changes associated with hyperparathyroidism.
However, these changes in the basic uremic and DI-OCTþ IV-OCT
groups were not remarkable. Orginal magnification  160.
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histochemical stainings for VDR and CaSR were performed using a
mouse monoclonal anti-VDR antibody (Santa Cruz Biotechnology,
Inc., CA, USA) and a mouse monoclonal anti-CaSR antibody
(Affinity BioReagents, Inc., CO, USA), respectively, as the primary
antibodies. The method using the dextran polymer conjugate two-
step visualization system developed by Vyberg and Nielsen (Dako
Envision System; HRP, Dako, Glostrup, Denmark) was applied.25
The slides were exposed to anti-VDR or anti-CaSR antibodies (1:100
or 1:1000 dilutions, respectively) for 1 h each at room temperature.
The slides were rinsed and then incubated with a peroxidase-labeled
dextran polymer conjugated to goat anti-mouse immunoglobulins
against the primary antibodies. The immunostaining was visualized
using a 3,3-diaminobenzidine substrate chromogen. PCNA expres-
sion level was also evaluated using a PCNA staining kit (ZYMED
Laboratories, Inc., CA, USA). These expression levels were
determined in individual glands by light microscopy (BX50,
Olympus, Tokyo, Japan). Three independent observers counted
the VDR- and PCNA-positive cells in 10 high-power fields with
approximately 400 cells per field at original magnification  400
(the number ratio of positive cells per 1000 cells; VDR- and PCNA-
labeling indexes), after which the average was taken. The ratio of
CaSR-positive area per total PTG was estimated for all PTG
specimens (CaSR-labeling index) using NIH image software
(National Institutes of Health, USA). The evaluation method of
these expression levels was the same as that used in our previous
study.11
Bone histopathological and histomorphometrical analyses
For in vivo fluorescence labeling, the rats received subcutaneous
injections of calcein 8 mg/kg body weight; (3,30-bis[N,N-bis (carboxy-
methyl) aminomethyl] fluorescein) (DOJINDO Laboratories,
Table 3 | Bone histomorphometric determinations of endosteal surface, intracortical area, and periosteal surface
of cortical bone
Parameter (unit)
Normal
(N=10)
Basic uremic
(N=8)
DI-OCT+IVOCT
(N=8)
DI-vehicle+IV-OCT
(N=8)
Uremic control
(N=8)
Endosteal surface
OS/BS (%) (13.778.7) 63.6718.3 24.2716.0**,##(a, b) 61.3716.0 76.0714.6
MS/BS (%) (16.977.6) 30.4710.7 11.1710.0**,##(a, b) 32.578.3 37.0714.7
MAR (mm/day) (1.2170.27) 2.4871.17 1.3070.99*,##(a, b) 4.0071.66 4.4771.63
BFR (mm3/mm2/year) (79.6746.6) 2997234 78.0790.1*,##(a, b) 4677208 5997345
Intracortical area
Fb.Ar/Ct.Ar (%) — 0.17170.484 Not detected##(b) 0.56270.783 1.21470.936
OS/BS (%) — 36.376.2 24.677.3**,##(a,b) 41.575.8 42.376.5
Ob.S/BS (%) — 15.676.7 6.7672.37**,#(a), ##(b) 16.977.1 25.279.2
Oc.S/BS (%) — 3.1672.60 4.2673.37#(b) 7.0673.16 8.3472.07
dLS/BS (%) — 1.7071.62 0.21870.409*,#(a),##(b) 1.8871.66 2.6471.08
MS/BS (%) — 10.474.2 3.0172.86**,##(a,b) 9.6674.67 12.874.4
MAR (mm/day) — 2.5470.57 0.72970.845**,##(a,b) 3.7470.82 3.3870.32
BFR (mm3/mm2/year) — 95.0738.7 12.6723.0**,##(a,b) 132770 161764
Periosteal surface
SLS/BS (%) (46.8717.9) 65.3722.3 21.6712.6**,#(a),##(b) 45.3713.6#(b) 68.4721.0
MS/BS (%) (39.0711.5) 44.2713.8 36.4720.0##(a),#(b) 63.8712.7 56.4713.4
MAR (mm/day) (1.6670.36) 2.4470.37 2.0970.49#(b) 2.8370.78 3.1470.67
BFR (mm3/mm2/year) (243796) 3927128 2887164##(a,b) 6657276 6487197
BFR, bone formation rate; OS/BS, osteoid surface; Ob.S/BS, osteoblast surface; Oc.S/BS, osteoclast surface; MAR, mineral apposition rate; MS/BS, mineralized surface; dLS/BS,
double-labeled surface; SLS/BS, single-labeled surface.
Data are means7s.d. **Po0.01 and *Po0.05 indicate significant differences compared with those of basic uremic group, and #Po0.05 and ##Po0.01 indicate significant
differences among treatment groups at the completion of study (a: vs DI-vehicle+IV-OCT, b: vs uremic control groups).
(weeks old)7 9 10 15 17 20 21
Baseline Completion
Normal diet High-P and low-Ca diet
IV-OCT (2.5 g/kg × 3 times/week) 
Lt. total Nx
DI-OCT
DI-vehicle
Blood sampling
Blood, PTG and bone
samplings
Rt. 2/3Nx
(1) Basic uremic
(4) Uremic control
(5) Normal
(3) DI-vehicle
+IV-OCT
(2) DI-OCT
+IV-OCT
Figure 8 | Experimental design. (1) Five/six nephrectomy and 8-
week high-P and low-Ca diet (basic uremic group), (2) with DI-OCT
and subsequent IV-OCT (DI-OCTþ IV-OCT group), (3) with DI-vehicle
and subsequent IV-OCT (DI-vehicleþ IV-OCT group), (4) with only
additional 4-week high-P and low-Ca diet (urmeic control group), and
(5) age-matched normal controls with normal diet (normal group). Rt.
2/3Nx: right 2/3 nephrectomy, Lt. total Nx: removal of left kidney.
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Table 4 | Abbreviations and bone histomorphometric parameters
Abbreviation Definition Unit
Abbreviations of general terms
Alb Albumin
BUN Blood urea nitrogen
Ca Calcium
CaSR Ca-sensing receptor
Cr Creatinine
DI-OCT Single direct OCT injection into bilateral PTGs
DI-vehicle Single direct vehicle injection into bilateral PTGs
ESRD End-stage of renal disease
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
Hb Hemoglobin
Hct Hematocrit
IV-OCT Intravenous OCT administrations (2.5mg/kg body weight, three times per week) for 4 weeks
OCT 22-oxacalcitriol (maxacalcitol)
P Phosphorus
PCNA Proliferating cell nuclear antigen
PCR Polymerase chain reaction
PTC Parathyroid cell
PTG Parathyroid gland
PTH Parathyroid hormone
s-HPT Secondary hyperparathyroidism
VDR Vitamin D receptor
Abbreviations of bone histomorphometric indices and units of cancellous bone
BV/TV Bone volume %
Tb.Th Trabecular thickness mm
Tb.N Trabecular number /mm
Tb.Sp Trabecular separation mm
Hy.Md.BV/BV Hypomineralized bone volume %
Fb.V/TV Fibrosis volume %
Ob.S/BS Osteoblast surface %
BFR/BS Bone formation rate mm3/mm2/year
Abbreviations of bone histomorphometric indices and units of cortical bone
Ct.Ar/T.Ar Cortical-total area %
Ma.Ar Marrow area mm2
Po.Ar./Ct.Ar Cortical porosity area %
Hy.Md.Ar/Ct.Ar Hypomineralized bone area %
Abbreviations of bone histomorphometric indices and units of endosteal surface, intracortical area and periosteal surface of cortical bone
Endosteal surface
OS/BS Osteoid surface %
MS/BS Mineralized surface %
MAR Mineral apposition rate mm/day
BFR Bone formation rate mm3/mm2/year
Intracortical area
Fb.Ar/Ct.Ar Fibrosis area %
OS/BS Osteoid surface %
Ob.S/BS Osteoblast surface %
Oc.S/BS Osteoclast surface %
dLS/BS Double-labeled surface %
MS/BS Mineralized surface %
MAR Mineral apposition rate mm/day
BFR Bone formation rate mm3/mm2/year
Periosteal surface
sLS/BS Single-labeled surface %
MS/BS Mineralized surface %
MAR Mineral apposition rate mm/day
BFR Bone formation rate mm3/mm2/year
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Kumamoto, Japan), 7 and 2 days before bone sampling. Immedi-
ately after the removal of all muscles, the right tibiae were fixed in
70% ethanol, embedded in methyl metacrylate without decalcifica-
tion and stained with Villanueva bone stain. Longitudinal sections
of the proximal portion of the tibiae and cross-sections at the
tibiofibular junctions of tibial shafts were cut to the respective
thicknesses of 20 and 30 mm using a microgrinding machine system
(KG4000; Exakt-Apparatebau, Norderstedt, Germany). Histomor-
phometrical analysis was performed according to a previously
reported method.26,27 All parameters except hypomineralized
volume (area) per bone volume (cortical area) (Hy.Md.V/BV and
Hy.Md.Ar/Ct.Ar) were calculated according to the recommendation
of the Histomorphometry Nomenclature Committee of the Amer-
ican Society of Bone and Mineral Research.28 Hy.Md.V (Ar) was
used as the parameter of mineralization abnormality associated with
osteitis fibrosa. Hypomineralized bone was salmon pink and was
distinguished from mineralized bone. Thus, Hy.Md.V was fitted to
the following equation: Hy.Md.Vþmineralized volume (Md.V)¼
bone volume (BV)osteoid volume (OV). Hy.Md.V (Ar)/BV
(Ct.Ar) was Hy.Md.V (Ar) referred to BV (Ct.Ar).
The region of the proximal tibial metaphysis that was 1–4 mm
distal to the growth plate-metaphyseal junction was studied and the
measurements are shown in Table 4 were taken. Cortical bone
determinations including those of the measurements and the
restrictive analyses of the endosteal surface, the intracortical area
(except for that of the normal group, because porosity was not
detected in the cortical bone) and the periosteal surface also shown
in Table 4 were taken.
Statistical analyses
Data were expressed as means7s.d. Baseline data among all the
treatment groups were analyzed by analysis of variance. The time
course of the changes in biochemical data among the rats in each
treatment group and the differences in all data between basic uremic
and each treatment groups were analyzed by analysis of variance
with post hoc multiple comparisons using Dunnett’s test. Biochem-
ical data, PTG/body weight ratio, mRNA expression levels,
immunohistochemical expression levels, and bone histomorpho-
metrical data among the treatment groups (DI-OCTþ IV-OCT, DI-
vehicleþ IV-OCT and uremic control) were analyzed by analysis of
variance with post hoc multiple comparisons using Tukey–Kramer’s
test. A P-value o0.05 was considered statistically significant.
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